



Since its founding in 2002, Penmix Ltd. is a leading CDMO-centric pharmaceutical company in Korea dedicated to the globalization of the Korean pharmaceutical industry and the development of quality pharmaceutical products with the belief that PENMIX protects the life and health of the humankind, prioritizing the importance of life.

PENMIX is a life science company consisting of healthy-minded people that remain dedicated to its role and has been working tirelessly as a global pharmaceutical company contributing to improving the quality of life.



History of

PENMIX

2022 Acquiring EUGMP and expecting to receive cGMP for expanding the business

Achieved B2B exporting revenue of 20 million USD in Asian market and total of 60 million USD including domestic sales

More than 90 million USD supply contracts made in Japan and countries of Southeast Asia,
Middle-East and South-America

2016 Completed expansion of the General inj. Factory

Completed the pre-filled syringe line for injection plant Received Minister's Commendation at the National Productivity Award

2013 Completed Injectable Factory construction

GMP certification Approval for Injectable Factory by KFDA

Established the automated warehouse Initiated Injectable Factory construction

Designed concept for the new injectable plant (EU / cGMP grade)

Awarded for "Large and Small business Cooperation" by the Prime Minister

Received a 10 million USD Export Tower Award from KITA(Korea International Trade Association)

2007 Acquired the Accreditation of Foreign Manufacturers from PMDA and expanded market to Japan

2003 Acquired KGMP certification

Separated from its parent Company Khunil Pharma. Established its Headquarters in Korea.



Why PENMIX



ABOUT PENMIX



Solid Financial

Structure



Supply

Expertise

Plant 1

Penicillin

Largest capacity in Korea

- No.1 market dominator in Korea and Japan
- Oral (tablet & suspension) Injectable (powder-filled & lyophilized vials)
- Commercialized in Cambodia, Japan, Macau, Malaysia, Mongolia, Myanmar, Singapore, Philippines, Vietnam and etc.



General Injectable

One of largest Injectable manufacturing sites in Asia

- Lyophilized, solution, powder, PFS, vials& bottles
- Commercialized in Japan, Turkey, Philippines, Vietnam and etc.

Revenue chart



ABOUT PENMIX

Key Business Aspects of

PENMIX







CDMO

As one of the top CDMOs, excellent understanding over pharmaceutical product

PENMIX maximizes the business efficiency by conducting the whole process of research planning, development, licensing, manufacturing, and so on. As we are an organization specialized in penicillin and injectables, we have our own R&D and RA specialists for whole CDMO project management.

Currently, we are an organization specializing in penicillin and injectables in accordance with global standards, and our aim is to grow into a professional research and development organization for all types of formulations in the future.

Growth

As a continuously growing company, aggressive on extending the market share

Since its foundation in 2002, PENMIX has been leading CDMO-centric pharmaceutical company in Korea dedicated to the globalization of the Korean pharmaceutical industry and development of high quality forpharmaceutical products. The virtuous circle of management system by profit-reinvestment has been the major growth factor for PENMIX since its foundation. It has constantly invested in developing high-value and differentiated products that require a challenging level of technology.

Global Network

Pre-Existing Partner Network in Overseas market

PENMIX, as an experienced CMO and CDMO, is offering the best solutions and products to its global customers including Japan, Europe and countries of the GCC and ASEAN. Especially Penmix affiliates with import/export specialist of pharmaceuticals in Japan as sister-company, Ohsong Pharm and Brio Pharma, and also planning to enter the Europe and USA market to become the genuine global leading company.

PENMIX PRODUCT

Marketing Capability

GLOBAL MARKET

Main target market is Japan, and we are preparing to expand to the big market like USA and EU.

As we are approved by the strict **PMDA** standard and expecting to receive **EUGMP** and **CGMP**, we are globally recognized as **high quality supplier for CMO/CDMO**.



Key Business Scope of

PENMIX

Across the Development and Contract Manufacturing Services

PENMIX LTD. is engaged in the customer value across the development and manufacturing spectrum for safe and high quality products to meet customer's expectation.

Contract Manufacturing

Penmix owns the largest
Penicillin and general injectable
producing facility in Korea,
and can provide under
the strict GMP management
in the complete

independent building for each.

Contract Development

By focusing on customers, Penmix delivers an extensive portfolio of penicillin and general injectable products and fulfills the evolving needs of the customers.

THE KEY
BUSINESS
SCOPE

injecta

Penicillin products

KGMP and JGMP certified

Capable of manufacturing tablet, dried suspension, Lyophilized and powder filling vial

3 Finished Product Export

Penmix is currently exporting penicillin and general injectables to Asia, Middle East and Latin America with expanding partnership to Europe and North/South America. Penmix has desire to closely work with new partners and to introduce high quality pharmaceutical products as well as parenteral products to the world.

General injectables

Newly constructed in 2013 complied with KGMP and JGMP

Capable of manufacturing lyophilized and solution vial/ ampoule,pre-filled syringe, big vial, and powered products



ABOUT PENMIX

1 Injectables

Composition	Package	Batch size
Amoxicillin Sodium 0.5 g (Potency) Pot. Clavulanate 0.1 g (Potency)	10 vials	80,000 vials
Amoxicillin Sodium 1 g (Potency) Pot. Clavulanate 0.2 g (Potency)	10 vials	50,000 vials
Piperacillin Sodium 1 g (Potency)	10 vials	54,000 vials
Piperacillin Sodium 2 g (Potency)	10 vials	32,000 vials
Ampicillin Sodium 0.5 g (Potency) Sulbactam Sodium 0.25 g (Potency)	10 vials	80,000 vials
Ampicillin Sodium 1 g (Potency) Sulbactam Sodium 0.5 g (Potency)	10 vials	50,000 vials
Amoxicillin Sodium 0.5 g (Potency) Sulbactam Sodium 0.25 g (Potency)	10 vials	80,000 vials
Amoxicillin Sodium 1 g (Potency) Sulbactam Sodium 0.5 g (Potency)	10 vials	50,000 vials
Piperacillin Sodium 2 g (Potency) Tazobactam Sodium 0.25 g (Potency)	10 vials	20,000 vials
Piperacillin Sodium 4 g (Potency) Tazobactam Sodium 0.5 g (Potency)	10 vials	30,000 vials

2 Oral dosage

아모크라

Composition	Package	Batch size
Amoxicillin Trihydrate 125 mg (Potency) Pot. Clavulanate 62.5 mg (Potency)	9 Tablets 10 Tropical Blisters	1,000,000 Tablets
Amoxicillin Trihydrate 250 mg (Potency) Pot. Clavulanate 125 mg (Potency)	10 Tablets 10 Tropical Blisters	500,000 Tablets
Amoxicillin Trihydrate 500 mg (Potency) Pot. Clavulanate 125 mg (Potency)	4 Tablets 10 Tropical Blisters	350,000 Tablets
Amoxicillin Trihydrate 437.5 mg (Potency) Pot. Clavulanate 62.5 mg (Potency)	8 Tablets 10 Tropical Blisters	450,000 Tablets
Amoxicillin Trihydrate 875 mg (Potency) Pot. Clavulanate 125 mg (Potency)	4 Tablets 10 Tropical Blisters	250,000 Tablets
Amoxicillin Trihydrate 25 mg/mL (Potency) Pot. Clavulanate 6.25 mg/mL (Potency)	40 Bottles (50mL) 20 Bottles (500mL)	40,000 Bottles (50mL) 5,000 Bottles (500mL)
Amoxicillin Trihydrate 40 mg/mL (Potency) Pot. Clavulanate 5.7 mg/mL (Potency)	40 Bottles (50mL) 20 Bottles (500mL)	40,000 Bottles (50mL) 5,000 Bottles (500mL)



1 Liquid vials

Composition	Package	Batch size
Ascorbic Acid 25g	1 vials	4,950 vials
Dexmedetomidine 118 ug/mL	5 vials	30,000 vials
Dexmedetomidine 236 ug/mL	5 vials	15,000 vials
Dexmedetomidine 590 ug/mL	5 vials	10,000 vials
Palonosetron 1.5 mg	5 vials	20,000 vials
Palonosetron 5.0 mg	1 vials	10,000 vials
Zoledronic Acid 5.33 mg/100 mL	1 vials	2,254 vials

2 Lyophilized vials

Composition	Package	Batch size
Daptomycin 500mg	1 vial	13,000 vials
Glutathione 600 mg	10 vials	30,000 vials
Glutathione 1,200 mg	10 vials	21,000 vials
Glutathione 2,000 mg	10 vials	22,352 vials
Vancomycin hydrochloride 500 mg	10 vials	50,000 vials
Vancomycin hydrochloride 1 g	1 vial	50,000 vials
Caspofungin 50 mg	10 vials	3,000 vials
Caspofungin 70 mg	10 vials	2,000 vials

에취라제™1,5001/

멀티미네륨5조

明目皇帝

펜티온

펜티오

Product Of PENMIX Developing Products

Composition	Strength	Composition	Strength
Sugammadex	2 mL, 5 mL	Ibandronate	1 mL PFS
Deoxycholate Acid	2 mL vial, 1 mL PFS	Levofolinate Calcium	200 mg, 450 mg
Epinephrine(Auto Inj.)	0.3 mg/0.3 mL	Peramivir	150 mg/15 mL
Ferric Hydroxide	360 mg/2 mL, 1800 mg/10 mL	Ramosetron	0.3 mg/2 mL
Daptomycin RF	350 mg, 500 mg		





14 Jeongdong-gil, Jung-gu, Seoul, Korea

Tel +82.2.2175.9844 **Fax** +82.2.703.8236 **Email** sjlee9@penmix.com

[Manufacturing Plant]

33 Georimak-gil, Jiksan-eup, Seobuk-ku, Cheonan-si, Chungnam, Korea Tel +82.41.580.5900 Fax +82.41.580.5906

www.penmix.com



Established in 2002-Subsidiary of Kuhnil Pharm (Since 1969)